Teng et al. were the first to investigate serum FSCN1 in patients with cancer, utilizing an ELISA kit for human FSCN1 from USCN Life Science (TX, USA) and reporting higher values in patients with NSCLC compared with healthy controls (which reported a median value of 3 ng/ml) [33]. Here, FSCN1 is linked to non-small cell lung carcinoma.